• Общие принципы и рекомендации по определению опухолевых маркеров в клинической практике гинеколога
ru К содержанию

Общие принципы и рекомендации по определению опухолевых маркеров в клинической практике гинеколога

HEALTH OF WOMAN. 2019.7(143): 31–38; doi 10.15574/HW.2019.143.31

А.В. Шумицкий, О.А. Бурка, Т.Н. Тутченко
Национальный медицинский университет им. А.А. Богомольца, г. Киев
ГУ «Институт педиатрии, акушерства и гинекологии имени академика Е.М. Лукьяновой НАМН Украины», г. Киев
МЛ «ДИЛА», г. Киев

Опухолевые маркеры играют большую роль во всех аспектах наблюдения за раком, начиная от скрининга до последующего наблюдения после лечения, и их разумное применение в клинической практике требует глубокого понимания основ патофизиологии, методов идентификации или тестирования, а также их роли в любом заболевании. Выявление может осуществляться либо в тканях, либо в жидкостях организма – асцитической, плевральной и, чаще всего, в сыворотке крови.

Клиническое использование онкомаркеров можно классифицировать на четыре группы: скрининг и раннее выявление, диагностическое подтверждение, прогноз и прогнозирование терапевтического ответа, мониторинг заболевания и рецидивов. Уровень онкомаркера в сыворотке крови в определенных ситуациях может использоваться при установлении диагноза, прогнозировании течения болезни или прогнозировании реакции на терапию. Мониторинг заболевания – это наиболее распространенное клиническое использование сывороточных маркеров опухолей. Растущая тенденция определения уровня онкомаркеров в сыворотке крови помогает выявить рецидив заболевания задолго до появления его явных клинических или рентгенологических признаков.

Ключевые слова: опухолевые маркеры (онкомаркеры), скрининг, диагностика, рак, антиген, злокачественность, лаборатория.

СПИСОК ЛИТЕРАТУРЫ

1. Sturgeon C, Hammond E, Chang SL, Sölétormos G, Hayes DF. NACB: Practice guidelines and recommendations for use of tumor markers in the clinic: Quality requirements [Section 2] 2008. Draft Guidelines 2006.

2. Waxman J. Tumor markers. Quart J Med. 1995;88:233–41.

3. Gold P, Freeman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorptions techniques. J Exp Med. 1965;121:439–62. https://doi.org/10.1084/jem.121.3.439; PMid:14270243 PMCid:PMC2137957

4. Koepke J. Molecular marker test standardization. Cancer. 1992;69:1578-81. https://doi.org/10.1002/1097-0142(19920315)69:6+<1578::AID-CNCR2820691312>3.0.CO;2-K

5. Andriole G, Crawford E, Grubb R, Buys S, Chia D, Church T, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. https://doi.org/10.1056/NEJMoa0810696; PMid:19297565 PMCid:PMC2944770

6. Cramer D, Bast R, Berg C, Diamandis E, Godwin A, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011;4:365-74. https://doi.org/10.1158/1940-6207.CAPR-10-0195; PMid:21372036 PMCid:PMC3085251

7. Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. https://doi.org/10.1056/NEJMoa0810084; PMid:19297566

8. Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295-303. https://doi.org/10.1001/jama.2011.766; PMid:2164268

9. Ofiara L, Navasakulpong A, Beaudoin S, Gonzalez A. Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer. Front Oncol. 2014;4:253. https://doi.org/10.3389/fonc.2014.00253; PMid:25295226 PMCid:PMC4170137

10. Advani P, Crozier J, Perez E. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy. Biomark Med. 2015;9:35-49. https://doi.org/10.2217/bmm.14.95; PMid:25605454

11. Donepudi M, Kondapalli K, Amos S, Venkanteshan P. Breast cancer statistics and markers. J Cancer Res Ther. 2014;10:506-11.

12. Diamandis EP. Tumor markers: Past, present, and future. In: Diamandis EP, Fritsche EP H Jr, Lilja H, Chan D, Schwartz M, editors. Tumor markers: Physiology, pathobiology, technology, and clinical applications. Washington DC: AACC Press; 2002. pp. 3–8.

13. Lindblom A, Liljegren A. Tumor markers in malignancies. Br Med J. 2000;320:424–7. https://doi.org/10.1136/bmj.320.7232.424; PMid:10669448 PMCid:PMC1117546

14. Cooper DL. Tumor markers. In: goldman, et al., editors. In: Cecil textbook of medicine.22nd ed. Philadelphia: WB Saunders Company; 2004.

15. Wu JT. Diagnosis and management of cancer using serological tumor markers. In: McPherson RA, Pincus MR, editors. Henry′s Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia: Elsevier Saunders; 2007.

16. Sokoll LJ, Chan DW. Clinical chemistry: Tumor markers. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. In Abeloff: Clinical Oncology. 3rd ed. Pennsylvania: Elsevier Churchill Livingston; 2004.

17. Goedegebuure PS, Liyanange U, Eberlein TJ. Tumor biology and tumor markers. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, editors. In: Townsend: Sabiston textbook of surgery. 17th ed. Philadelphia: Elsevier Saunders; 2004.

18. Khatcheressian J, Hurley P, Bantug E, Esserman L, Grunfeld E, Halberg F, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961-5. https://doi.org/10.1200/JCO.2012.45.9859; PMid:23129741

19. Marić P, Ozretic P, Levanat S, Oreskovic S, Antunac K, Beketic Oreskovic L. Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol. 2011;35:241-7.

20. Brooks M. Breast cancer screening and biomarkers. Methods Mol Biol. 2009;472:307-21. https://doi.org/10.1007/978-1-60327-492-0_13; PMid:19107439

21. Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer — European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281-93. https://doi.org/10.1159/000089260; PMid:16254457

22. Bieglmayer C, Szepesi T, Kopp B, Hoffmann G, Petrik W, Guettuoche K, Grundler S, Gregorits M, Strasser M: CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumor Biol 1991;12:138-148. https://doi.org/10.1159/000217699; PMid:2068512

23. Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, Robertson JF: CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001;37:355-363. https://doi.org/10.1016/S0959-8049(00)00396-8

24. Sturgeon CM, Duffy MJ, Stenman UH, y cols. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:11-79. https://doi.org/10.1373/clinchem.2008.105494; PMid:18801938

25. Molina R, AUge Jm, Farrus B, Zanon G, Pahisa J, Muñoz M, Torne M, Filella X, Escudero JM, Fernandez P, Velasco M. Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. Clin Chem 2011;56:1148-57. https://doi.org/10.1373/clinchem.2009.135566; PMid:20472825

26. Molina R, Auge Jm, Escudero JM, Fiella X, Zanon G, Pahisa J, Farrus B, Muñoz M, Velasco M. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumor Biol 2010;31:171-180). https://doi.org/10.1007/s13277-010-0025-9; PMid:20361287

27. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Whittliff Jl. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche H Jr, Lilja H, Chan D, Schwartz M, editors. In Tumor markers: Physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press; 2002.

28. Molina R, Escudero JM, Muñoz M, Auge JM, Filella X. Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med 2012;50:5-21. https://doi.org/10.1515/cclm.2011.822; PMid:22505536

29. Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer — European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281-93. https://doi.org/10.1159/000089260; PMid:16254457

30. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligandbinding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-7. https://doi.org/10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W

31. Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103:164-73. https://doi.org/10.1002/cncr.20761; PMid:15565575

32. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004;9:617-32. https://doi.org/10.1634/theoncologist.9-6-617; PMid:15561806

33. Hammond E et al. American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010;28:2784-95. https://doi.org/10.1200/JCO.2009.25.6529; PMid:20404251 PMCid:PMC2881855

34. Wolf et al. American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2007;25:118-45. https://doi.org/10.1200/JCO.2006.09.2775; PMid:17159189

35. Yin B, Lloyd K. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371-5. https://doi.org/10.1074/jbc.M103554200; PMid:11369781

36. Yin B, Dnistrian A, Lloyd K. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98:737-40. https://doi.org/10.1002/ijc.10250; PMid:11920644

37. Riska A, Leminen A. Updating on primary fallopian tube carcinoma. Acta Obstet Gynecol Scand. 2007;86:1419-26. https://doi.org/10.1080/00016340701771034; PMid:18027113

38. Togo Peraza J, Gómez Pinto J, Togo Osuna L, Montoya Romero J. [Primary carcinoma of the peritoneum. Case report and literature review]. Ginecol Obstet Mex. 2014;82:344-9.

39. Dao M, Alwan L, Gray H, Tamimi H, Goff B, Liao J. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2013;130:295-9. https://doi.org/10.1016/j.ygyno.2013.04.055; PMid:23632207 PMCid:PMC4527599

40. Esselen K, Rodriguez N, Growdon W, Krasner C, Horowitz N, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012;127:51-4. https://doi.org/10.1016/j.ygyno.2012.05.026; PMid:22659193

41. Moss E, Hollingworth J, Reynolds T. The role of CA125 in clinical practice. J Clin Pathol. 2005;58:308-12. https://doi.org/10.1136/jcp.2004.018077; PMid:15735166 PMCid:PMC1770590

42. Omar Y, al Naqeeb N, el Nas S, Awwad A, Foudeh M, Safadi N, et al. Serum levels of CA 125 in patients with gastrointestinal cancers. Tumour Biol. 1989;10:316-23. https://doi.org/10.1159/000217631; PMid:2480631

43. Sikaris K. CA125-a test with a change of heart. Heart Lung Circ. 2011;20:634-40. https://doi.org/10.1016/j.hlc.2010.08.001; PMid:20822954

44. Turgut O, Tandogan I, Yilmaz M, Gul I, Gurlek A. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. Int J Cardiol. 2010;145:71. https://doi.org/10.1016/j.ijcard.2009.04.030; PMid:19446349

45. ARUP Laboratories. Risk of Ovarian Malignancy Algorithm (2013). Available from: [https://www.aruplab.com/].

46. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513-22. https://doi.org/10.1002/ijc.28384; PMid:23852704 PMCid:PMC4217376

47. Madhav Nagpal, Shreya Singh,1 Pranshu Singh,2 Pallavi Chauhan,3 and Meesam Abbas Zaidi. Tumor markers: A diagnostic tool. Natl J Maxillofac Surg. 2016 Jan-Jun; 7(1): 17–20. https://doi.org/10.4103/0975-5950.196135; PMid:28163473 PMCid:PMC5242068

48. Yoshitaka Tsubono, M.D, Shigeru Hisamichi, M.D. May 6, 2004. N Engl J Med 2004; 350:2010-2011. https://doi.org/10.1056/NEJM200405063501922; PMid:15128908.

49. Chen et al. Liver cancer screening in China: practices and its extended questions. Hepatoma Res 2019;5:12. https://doi.org/10.20517/2394-5079.2019.03.

50. Screening for Prostate Cancer. US Preventive Services Task Force. Recommendation Statement. JAMA. 2018;319(18):1901-1913. https://doi.org/10.1001/jama.2018.3710; PMid:29801017.

51. Markus Hoffmann. Medical Scientific Liaison Europe, Abbott Diagnostics.

52. American Society of Clinical Oncology / ASCO. Available from: [https://www.asco.org/].

53. The EAU Guidelines on Bladder Cancer 2016 http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/#5

54.  Clin Chem. 2010 Jun;56(6):e1-48. doi: 10.1373/clinchem.2009.133124. Epub 2010 Mar 5.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.

55. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2013.

56. Американська асоціація онкологів: Colorectal Cancer Early Detection, Diagnosis, and Staging, 2017.